MarketPulse

ASCENIV

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Lowey Dannenberg, P.C.

ADMA Biologics Under SEC Investigation for Alleged Channel Stuffing Scheme

ADMA Biologics faces SEC investigation for allegedly inflating 2025 revenue growth from -3% actual to +20% reported through channel stuffing practices with distributors.
ADMAsecurities fraudinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Bleichmar Fonti & Auld Llp

ADMA Biologics Faces Securities Fraud Probe Over Channel Stuffing Claims

ADMA Biologics under fraud investigation after Culper Research alleged channel stuffing masked -3% actual revenue decline reported as +20% growth, causing 29% stock collapse.
ADMAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

ADMA Biologics Under Investigation for Alleged Channel Stuffing and Securities Violations

Law firm Kirby McInerney investigates $ADMA for potential securities violations. Culper Research alleges channel stuffing and undisclosed related-party distribution practices inflated 2025 growth.
ADMAsecurities fraudclass action investigation
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ADMA Biologics Plunges 16% as Short Seller Alleges Channel Stuffing Scheme

ADMA Biologics shares crashed 16% after short seller accused the company of inflating revenues through improper rebates and extended payment terms to distributors.
ADMAsecurities fraudbiopharmaceutical
BenzingaBenzinga··Glancy Prongay Wolke & Rotter Llp

ADMA Biologics Faces Securities Fraud Probe Over Channel Stuffing Allegations

ADMA Biologics faces securities fraud investigation for alleged channel stuffing, resulting in 29.1% stock decline to $9.63 per share.
ADMAsecurities fraudstock decline